The Food and Drug Administration (FDA) of the United States have given the authorization for a new monoclonal antibody treatment that is working effectively against the Omicron covid-19 variant.
The emergency use authorization for the bebtelovimab has been for the treatment of the mild to moderate corona virus in the adults and pediatric patients around 12 years of age, who have been at high risk for the serious diseases. The monoclonal treatment is developed by Eli Lilly and Co., and the company has announced that, the United States is going to be purchasing 600,000 doses of the drug in a deal of around 720 million dollars.
This emergency use authorization from the US FDA has come as a good news for the new people, who are at high risk of the serious corona virus, and the mutations of the Omicron covid-19 variant had rendered ineffective several of the past available treatments of the monoclonal treatment, along with leaving the doctors along with lesser options of the treatment.
Dr. Patrizia Cavazzoni, director of the Center for Drug Evaluation and Research of US FDA said, this move is making available another treatment of monoclonal antibody that is showing the activity against the Omicron corona virus variant and at a time when they are going to seek for the future increase in the supply.
The director also said that, this approval has been an important step in meeting the need for more number of tools for the purpose of treating the patients as the new covid-19 variants of the covid-19 continuing to emerge.